TY - JOUR
T1 - RAB14 activates MAPK signaling to promote bladder tumorigenesis
AU - Chao, Haichao
AU - Deng, Leihong
AU - Xu, Fanghua
AU - Fu, Bin
AU - Zhu, Zunwei
AU - Dong, Zhifeng
AU - Liu, Yen-Nien
AU - Zeng, Tao
N1 - Funding Information:
This work was supported by funds from the National Nature Science Foundation of China (81560420 to T.Z.) and the Research Program from Health and Family Planning Commission of Jiangxi Province (20165032 to H.C.). Conflict of Interest Statement: None declared.
Publisher Copyright:
© 2019 The Author(s). Published by Oxford University Press. All rights reserved.
PY - 2019/11/25
Y1 - 2019/11/25
N2 - Bladder cancer (BC) is a fatal invasive malignancy accounting for approximately 5% of all cancer deaths in humans; however, the underlying molecular mechanisms and potential targeted therapeutics for BC patients remain unclear. We report herein that RAB14 was overexpressed in BC tissues and cells with high metastatic potential and its abundance was significantly associated with lymph node metastasis (P = 0.001), a high-grade tumor stage (P = 0.009), poor differentiation (P < 0.001) and unfavorable prognoses of BC patients (P = 0.003, log-rank test). Interference by RAB14 mediated a reduction in the TWIST1 protein and inhibited cell migration and invasion (P < 0.05). Moreover, silencing RAB14 reduced cell proliferation and induced apoptosis in vitro and suppressed tumorigenesis in a mouse xenograft model. We demonstrated that RAB14-promoted BC cancer development and progression were associated with activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase signaling through upregulation of MAPK1/MAPK8 and downregulation of dual-specificity protein phosphatase 6/Src homology 2 domain containing transforming protein/Fos proto-oncogene, AP-1 transcription factor subunit (FOS). We provide evidence that RAB14 acts as a tumor promoter and modulates the invasion and metastatic potential of BC cells via activating the MAPK pathway.
AB - Bladder cancer (BC) is a fatal invasive malignancy accounting for approximately 5% of all cancer deaths in humans; however, the underlying molecular mechanisms and potential targeted therapeutics for BC patients remain unclear. We report herein that RAB14 was overexpressed in BC tissues and cells with high metastatic potential and its abundance was significantly associated with lymph node metastasis (P = 0.001), a high-grade tumor stage (P = 0.009), poor differentiation (P < 0.001) and unfavorable prognoses of BC patients (P = 0.003, log-rank test). Interference by RAB14 mediated a reduction in the TWIST1 protein and inhibited cell migration and invasion (P < 0.05). Moreover, silencing RAB14 reduced cell proliferation and induced apoptosis in vitro and suppressed tumorigenesis in a mouse xenograft model. We demonstrated that RAB14-promoted BC cancer development and progression were associated with activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase signaling through upregulation of MAPK1/MAPK8 and downregulation of dual-specificity protein phosphatase 6/Src homology 2 domain containing transforming protein/Fos proto-oncogene, AP-1 transcription factor subunit (FOS). We provide evidence that RAB14 acts as a tumor promoter and modulates the invasion and metastatic potential of BC cells via activating the MAPK pathway.
UR - http://www.scopus.com/inward/record.url?scp=85068183482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068183482&partnerID=8YFLogxK
U2 - 10.1093/carcin/bgz039
DO - 10.1093/carcin/bgz039
M3 - Article
C2 - 30809635
SN - 0143-3334
VL - 40
SP - 1341
EP - 1351
JO - Carcinogenesis
JF - Carcinogenesis
IS - 11
ER -